VIENNA, Austria, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying Specific Active Immunotherapies (SAITs), today announced an exclusive collaboration and license agreement with Frontier Biotechnologies Inc. (688221.SH), a commercial-stage biopharmaceutical company, for the development and commercialization of AFFITOPE ® AT04 for the treatment of patients with hypercholesterolemia in the Greater China region, including mainland China, Hong Kong, Macau and Taiwan. AFFITOPE ® AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published. Shanghai-based Lynx Financial served as the sole financial advisor in this transaction. Study Purpose: The purpose of this open-label study is to evaluate the safety and efficacy of combination therapy with albuvirtide plus 3BNC117 in participants with multidrug-resistant HIV. Sgherza, D.; Pentassuglia, S.; Altieri, V.G.; Mascolo, G.; De Sanctis, M.; Di Iaconi, C. Integrating biodegradation and ozone-catalysed oxidation for treatment and reuse of biomass gasification wastewater. J. Water Process Eng. 2021, 43, 102297. [ Google Scholar] [ CrossRef] Currently there is limited data on antiviral therapy for hospitalized AIDS patients with complicated opportunistic infections. The two-drug regimen containing ABT can rapidly inhibit viral replication, improve cellular immune function of patients, and is safe and effective for treatment naive and experienced patients withlow CD4+ T cell count.

In the in vitroanti-HIV-1 combination therapy, Albuvirtidehad synergistic effect with zidovudine (AZT) and saquinavir (SQV), and additive effect with efavirenz (EFV) and enfuvirtide (T20).Chin Med J (Engl) article, 2020: Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

Froma100 mL infusion bag (bottle) of 0.9% sodium chloride solutionwithdraw 12mLto discard.The remaining 88mL of 0.9%sodium chloride solution will be used for the AIKENING TMreconstitution. Two Phase I, one Phase II clinical trials of AIKENING TMhave been completed, and one Phase IIIis ongoing and an interim analysis is reported. A total of 294 infected subjects were enrolled in the trials.170 patients with HIV-1 infection have been exposed to AIKENING TM.The safety assessment of AIKENING TMwas primarily based on theongoing randomized, controlled phase III clinical trial (TALENT study) in HIV-1 infected patients previously treated with antiretrovirals, in which the treatment group received the AIKENING TM(onceaweek, intravenousinfusion) and Lopinavir/ Ritonavir (LPV/r) combination therapy, and the control group received the standard 3-drug regimen of LPV/r + Tenofovir (TDF) or Zidovudine (AZT) + Lamivudine (3TC). Theinterim analysis summarized the safety data ofthe treatment group(n = 93) and the control group(n = 99) patients who completed24 to 48-weektreatment.Dr. Sheng-Hua He, Director of the Department of Infection, Chengdu Public Health Clinical Medical Centersaid, "Treating hospitalized AIDS patients who are critically ill, especially those who are prone to opportunistic infections and have comorbidities, have been difficult and complicated due to limited treatment options. The ABT-containing regimen has no obvious toxicity to liver and kidney, which is conducive to the rapid initiation of ART treatment. ABT, a new fusion inhibitor given once weekly, is the first and only long-acting injectable available as a two-drug regimen for treatment-experienced patients with HIV-1 replication Participants are adults with HIV who have received ART for at least 6 months. Participants have been on a failing ART regimen for at least 8 weeks prior to screening or had treatment failure within the past 8 weeks of screening and are off therapy. Chen, Y.; Jiang, X.; Xiao, K.; Shen, N.; Zeng, R.J.; Zhou, Y. Enhanced volatile fatty acids (VFAs) production in a thermophilic fermenter with stepwise pH increase—Investigation on dissolved organic matter transformation and microbial community shift. Water Res. 2017, 112, 261–268. [ Google Scholar] [ CrossRef] Frontier Biotechnologies Inc. Efficacy and safety of albuvirtide for injection combined with LPV/r for treatment of HIV-1-infected patients failed first-line antiretroviral therapy. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 18, 2015. NLM Identifier: NCT02369965. Accessed April 4, 2023